FAHA

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Sunday, April 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Retrieved on: 
Tuesday, March 12, 2024
Abstract, Chlorine, Survival, SOT, University, Doctor of Philosophy, MD, Code, FAHA, Society, Translation, Safety, Tokyo Stock Exchange, ALI, Edema

In this study, single-dose and multi-dose treatments were evaluated.

Key Points: 
  • In this study, single-dose and multi-dose treatments were evaluated.
  • The primary endpoint was the mean change in the pulmonary function measure PaO2/FiO2, which is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
  • Additional endpoints included survival, lung mechanics, lung injury, and edema formation evaluated by chest x-ray.
  • Cl2 gas concentration of 210 ppm x 30 min was expected to result in a 20 - 30% mortality rate (Fukuda 2015).

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

Retrieved on: 
Wednesday, March 27, 2024
Element, Myocardial infarction, FACC, Interest, AMI, Growth, Lupus, Cardiology, SPA, Patient, Columbia University, NYU, Faculty, FAHA, MBA, FESC, Heart failure, MPH, Safety, OPUS, FDA, Autoimmune disease, Food, Hospital, Pharmaceutical industry

The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.

Key Points: 
  • The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.
  • The collaboration with Idorsia is a great example of Viatris' strategy in action—adding two late-stage potential blockbuster assets, selatogrel and cenerimod—and connecting Idorsia's highly productive drug development team and innovation engine with Viatris' existing infrastructure and experience.
  • The Company will review key elements of the collaboration including how Viatris can make a difference in the delivery of these assets.
  • An archived version also will be available following the live event and can be accessed at the same location for a limited time.

The American Diabetes Association Announces the 2024 National Scientific and Health Care Achievement Award Winners

Retrieved on: 
Wednesday, March 6, 2024
Reward, Bachelor of Science, Nursing, Royal College of Pathologists, Doctor of Philosophy, Pregnancy, University, FRCP, CUPS, Social media, American Diabetes Association, Doctor of Science, MB, FESC, Lois Jovanovic, FACP, FACE, FACC, MRCP, Book, Physician, Female, Doctor of Pharmacy, Life, Learning, Prognosis, Prediabetes, Insulin resistance, Lond, Research, FAHA, Interest, Patient, Causality, Public

ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.

Key Points: 
  • ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.
  • The awards honor academics, health care providers, and educators who have contributed to substantial advances in diabetes care and research.
  • ), FMedSci is the recipient of the 2024 Banting Medal for Scientific Achievement, which recognizes significant long-term contributions to the understanding, treatment, or prevention of diabetes.
  • Parker, PhD is the recipient of the 2024 Outstanding Scientific Achievement Award, which recognizes research in diabetes that demonstrates particular independence of thought and originality.

Kelvin Health joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

Retrieved on: 
Wednesday, February 28, 2024
Cornell University, Innovation, American Heart Association, FAHA, Cardiovascular disease, Weill Cornell Medicine, American Heart, Network, Science

SOFIA, Bulgaria, Feb. 28, 2024 /PRNewswire/ -- Kelvin Health, diagnostic solution aiming to advance the standard of vascular care by applying modern AI to mobile thermography imaging, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

Key Points: 
  • SOFIA, Bulgaria, Feb. 28, 2024 /PRNewswire/ -- Kelvin Health, diagnostic solution aiming to advance the standard of vascular care by applying modern AI to mobile thermography imaging, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network.
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • The Innovators' Network is a health care technology consortium that connects entrepreneurs, providers, researchers, and payers.
  • Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies.

MelliCell Announces Dr. Fatima Cody Stanford as New Advisory Board Member

Retrieved on: 
Tuesday, February 27, 2024
Diabetes, FAAP, Obesity, FAHA, Hospital, MPA, MBA, DSM-IV codes, MGH, FACP, Human, CNN, PBS, Associate, HMS, Pediatrics, Massachusetts General Hospital, Harvard Medical School, Adipose tissue, Research, Public

This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.

Key Points: 
  • This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.
  • Dr. Stanford brings to MelliCell a rich legacy of expertise in obesity medicine as an Associate Professor of Medicine and Pediatrics at Massachusetts General Hospital (MGH) / Harvard Medical School (HMS).
  • As MelliCell prepares for its upcoming funding round, the addition of Dr. Stanford to the advisory board marks a pivotal moment in the company's trajectory towards establishing new standards in metabolic disease treatment.
  • "Joining MelliCell's dynamic team is an exciting opportunity to advance the fight against obesity through our focused research on adipose tissue," expressed Dr. Stanford.

PUER Joins Campden Wealth As a Corporate Partner to Provide Multigenerational Health Resources

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Education, Cholesterol, Physician, Molecular medicine, FAHA, Drug development, System, Health, Therapy, UHNW, Genome, FACC, Genomics, Trial of the century, Management

ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.

Key Points: 
  • ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.
  • PUER is joining the Campden Wealth community as one of Campden Wealth's select corporate partners for 2024.
  • PUER offers a high-touch, high-science, multigenerational concierge program with the most comprehensive health planning for families.
  • A centennial time horizon aims to complement multigenerational family education and resources facilitated by Campden Wealth.

Hippocratic AI Launches Nurse Advisory Council to Help Guide Development of Safety-Focused Healthcare LLM

Retrieved on: 
Wednesday, February 14, 2024
Research, Doctor of Philosophy, RN, Case management, Harvard University, Pulse, Lead, LLM, RNC-MNN, Health care, Health, Host, Workforce, Mortality, Health equity, Hippocrates, UCSF, CMSA, BSN, MIT, RNS, Spider-Man, MBA, Broad Institute, Council, Disease, Massachusetts General Hospital, ACM, CCM, Texas Health Resources, Hospital, Digital, Learning, Safety, Knowledge, PALO, Digital health, AI, FAHA, World Health Organization, Entrepreneurship, CMAC, DNP, Patient, Patient safety, Nursing

PALO ALTO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Hippocratic AI today announced the launch of its Nurse Advisory Council, comprised of registered nurses (RNs) from leading healthcare systems and digital healthcare enterprises.

Key Points: 
  • PALO ALTO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Hippocratic AI today announced the launch of its Nurse Advisory Council, comprised of registered nurses (RNs) from leading healthcare systems and digital healthcare enterprises.
  • The Nurse Advisory Council, alongside Hippocratic AI’s Physician Advisory Council , will help shape the company’s safety-focused Large Language Model (LLM) for healthcare and ensure that it is ready for deployment.
  • The Nurse Advisory Council is the latest in a string of collaborative initiatives designed to ensure that Hippocratic AI’s LLM is as safe and impactful as possible.
  • “We designed Hippocratic AI’s Nurse Advisory Council to ensure that their expert insight plays a critical role in our LLM development.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024
Software, Research, General Health, Technology, Medical Devices, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Shift, CNN, Conference, ISC, Atrial fibrillation, DTG, Neurosurgery, Workflow, FAHA, Diagnosis, ICM, Aneurysm, Intraparenchymal hemorrhage, AI, MLS, Automation, MD, Single Center, Abstract (summary), Stroke, Viz, ICH, Patient, Groin, Triage, Intervention, Artificial intelligence, CSC, UIA, Intracranial hemorrhage, Associate, University of Kentucky, University, McGovern Medical School, Ambient occlusion, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

DynaMed® Named 2024 Best in KLAS for Clinical Decision Support

Retrieved on: 
Wednesday, February 7, 2024
Software, FAHA, Research, Feedback, FACP, EBSCO, FACC, Information services, Trust, Human, Nursing

IPSWICH, Mass., Feb. 7, 2024 /PRNewswire-PRWeb/ -- DynaMed®, a Clinical Decisions resource from EBSCO Information Services (EBSCO), is named the top performing point-of-care clinical reference tool in the 2024 Best in KLAS Software and Services report. KLAS, a research firm that specializes in monitoring and reporting the performance of health care vendors, ranked DynaMed the number one clinical decision support point-of-care reference tool among health care organizations. This is the third year that DynaMed has been ranked number one clinical decision support reference tool, and the fifth year the tool has been included in the Best in KLAS: Software and Services report.

Key Points: 
  • IPSWICH, Mass., Feb. 7, 2024 /PRNewswire-PRWeb/ -- DynaMed ®, a Clinical Decisions resource from EBSCO Information Services (EBSCO), is named the top performing point-of-care clinical reference tool in the 2024 Best in KLAS Software and Services report .
  • KLAS , a research firm that specializes in monitoring and reporting the performance of health care vendors, ranked DynaMed the number one clinical decision support point-of-care reference tool among health care organizations.
  • This is the third year that DynaMed has been ranked number one clinical decision support reference tool, and the fifth year the tool has been included in the Best in KLAS: Software and Services report.
  • The Best in KLAS awards are based on extensive feedback and evaluations from healthcare professionals across the nation.